Appeals Court Revives RICO Off-Label Suit Against Abbott
This article was originally published in The Pink Sheet Daily
Executive Summary
Seventh Circuit reinstates employer benefit funds’ complaint over off-label promotion of Depakote, allowing them to make case they were not properly compensated; courts have issued disparate opinions in such cases.
You may also be interested in...
Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail
Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.
Abbott’s Depakote Off-Label Settlement With DoJ Includes Court Probation
In a new twist, Abbott’s CEO and board must certify company’s compliance program with the court’s probation office. The requirements of the $1.5 billion settlement will transfer to Abbvie, the pharma company spinning out of Abbott.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.